SK Bioscience to Pursue IPO Next Year... NH and KTB as Lead Underwriters
[Asia Economy Reporter Cho Hyun-ui] SK Bioscience announced on the 26th that it has selected NH Investment & Securities as the lead underwriter and Korea Investment & Securities as the joint underwriter to promote its initial public offering (IPO). SK Bioscience is a vaccine-specialized company spun off from SK Chemicals in July 2018.
On the same day, SK Bioscience stated, "We are pursuing an IPO to secure investment funds for business expansion and to accelerate additional growth." The target listing date is 2021.
SK Bioscience owns self-developed vaccines such as SKYCellflu4, the world's first quadrivalent cell-based influenza vaccine; SKYZoster, the world's second shingles vaccine; and SKYVaricella, the second domestically developed chickenpox vaccine.
Recently, the company has also entered overseas markets by signing a contract for contract manufacturing (CMO) to supply COVID-19 vaccines with the global pharmaceutical company AstraZeneca.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
An SK Bioscience official said, "We will execute the IPO under conditions that can receive an appropriate corporate valuation."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
